A treasure trove of intracellular cancer drug targets remains hidden behind cell membranes. However, engineered pathogen-derived toxins such as Shiga toxins can deliver small or macromolecular drugs to specific intracellular organelles. After binding to ganglioglobotriaosylceramide (Gb3, CD77), the non-toxic subunit B (StxB) of the Shiga-holotoxin is endocytosed and delivers its payload by a unique retrograde trafficking pathway via the endoplasmic reticulum to the cytosol. This review provides an overview of biomedical applications of StxB-based drug delivery systems in targeted cancer diagnosis and therapy. Biotechnological production of the Stx-material is discussed from the perspective of developing efficacious and safe therapeutics.

细胞内癌药物靶标的宝库仍然隐藏在细胞膜的后面。但是，工程改造的病原体衍生毒素（例如志贺毒素）可以将小分子或大分子药物传递给特定的细胞内细胞器。结合到神经节红肉豆糖基神经酰胺（Gb3，CD77）后，志贺全毒素的无毒亚基B（StxB）被内吞并通过内质网通过独特的逆行运输途径将其有效载荷传递到细胞质。这篇综述概述了基于StxB的药物递送系统在靶向癌症诊断和治疗中的生物医学应用。从开发有效和安全的治疗方法的角度讨论了Stx材料的生物技术生产。